Consensus Amphastar Pharmaceuticals, Inc.

Stocks

AMPH

US03209R1032

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 20/10/2026 BST			5-day change	1st Jan Change
25.94 ^USD	-0.77%		-0.42%	-3.14%

08-18	Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating	MT
08-07	Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026

Evolution of the Average Target: Amphastar Pharmaceuticals, Inc.

Evolution of the Target Price: Amphastar Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Amphastar Pharmaceuticals, Inc.

5.IIttXoY85YAMRC0MtgKzXQzkpLgfgeV0xjSbyQpAqr4.V9EyCeEKsNVrJUNTjm3gNXaIxfpPtN0f_3OvoWUpko9L3Sxn1k2kwl0QaA~f448590f23f00c061df8d6f56b97207a

Analysts' recommendations: Amphastar Pharmaceuticals, Inc.

08-18	Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating	MT
06-29	BofA Securities Downgrades Amphastar Pharmaceuticals to Underperform From Neutral, Cuts Price Target to $20 From $25	MT
06-29	BofA Securities Downgrades Amphastar Pharmaceuticals to Underperform, $20 Price Target	MT
05-14	Amphastar Shares Fall After Wells Fargo Downgrade	MT
05-14	Wells Fargo Downgrades Amphastar Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $19 From $30	MT
04-21	Jefferies Downgrades Amphastar Pharmaceuticals to Hold From Buy, Adjusts Price Target to $22 From $30	MT
01-07	BofA Securities Adjusts Price Target on Amphastar Pharmaceuticals to $30 From $31, Maintains Neutral Rating	MT
01-07	Biopharma Sector Enters 2026 With Clearer Outlook, Key Catalysts, BofA Says	MT
12-09	Barclays Initiates Amphastar Pharmaceuticals at Equalweight With $30 Price Target	MT
09/10/25	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
09/10/25	BofA Cuts Price Target on Amphastar Pharmaceuticals to $31 From $32	MT
12/08/25	Needham Upgrades Amphastar Pharmaceuticals to Buy From Hold, Price Target is $36	MT
12/05/25	JPMorgan Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $30 From $45	MT
21/04/25	BofA Adjusts Price Target on Amphastar Pharmaceuticals to $31 From $36	MT
04/02/25	Piper Sandler Downgrades Amphastar Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $36 From $66	MT
03/02/25	BofA Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $46	MT
05/03/24	JPMorgan Initiates Amphastar Pharmaceuticals With Overweight Rating, Price Target is $60	MT
17/11/23	BofA Securities Initiates Amphastar Pharmaceuticals at Neutral Rating With $63 Price Target	MT
25/07/23	Jefferies Reinstates Buy Rating on Amphastar Pharmaceuticals With $70 Price Target	MT
17/05/23	Wells Fargo Adjusts Price Target on Amphastar Pharmaceuticals to $44 From $40, Maintains Equal-Weight Rating	MT
25/10/22	Piper Sandler Adjusts Amphastar Pharmaceuticals' Price Target to $40 From $43, Keeps Overweight Rating	MT
21/10/22	Jefferies Assumes Amphastar Pharmaceuticals at Buy with $36 Price Target	MT
29/07/22	Capital One Initiates Amphastar Pharmaceuticals at Overweight Rating With $44 Price Target	MT
11/04/22	Northland Adjusts Price Target on Amphastar Pharmaceuticals to $43 From $33, Keeps Outperform Rating	MT
08/04/22	Piper Sandler Raises Price Target for Amphastar Pharmaceuticals to $47 From $35, Maintains Overweight Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AMPHASTAR PHARMACEUTICALS, INC.					-13.92%
	ELI LILLY AND COMPANY					+7.22%
	JOHNSON & JOHNSON					+10.09%
	ABBVIE INC.					-0.03%
	ROCHE HOLDING AG					+1.02%
	MERCK & CO., INC.					+10.39%
	NOVARTIS AG					-0.24%
	ASTRAZENECA PLC					+27.41%
	AMGEN INC.					-7.05%
	GILEAD SCIENCES, INC.					+4.63%
	Average					+3.95%
	Weighted average by Cap.					+6.25%